Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Jun 15;50(12):3652-6.

Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures

Affiliations
  • PMID: 2340513

Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures

R W Brueggemeier et al. Cancer Res. .

Abstract

7 alpha-(4'-Amino)phenylthio-1,4-androstadiene-3,17-dione (7 alpha-APTADD), a potent enzyme-activated irreversible inhibitor, was examined in two different human cell culture lines, MCF-7 human mammary carcinoma cells and JAr choriocarcinoma cells. Both the MCF-7 and JAr cell culture systems exhibit aromatase activity, and 7 alpha-APTADD was evaluated for its aromatase-inhibitory activity, for its ability to inactivate the enzyme complex, and for the time course of recovery of enzymatic activity. This inhibitor produced a dose-dependent inhibition of aromatase activity in MCF-7 cells and in JAr cells, with EC50 values of 91 and 7.3 nM, respectively. Two other steroidal inhibitors, 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione and 4-hydroxyandrostenedione, produced similar dose-response curves and EC50 values, while the nonsteroidal aminoglutethimide was less effective. Both cell culture systems exhibited prolonged inhibition of aromatase activity following exposure to 7 alpha-APTADD, suggesting enzyme inactivation by this inhibitor. Thus, 7 alpha-APTADD is an effective inhibitor of aromatase in MCF-7 mammary carcinoma cells and in JAr choriocarcinoma cells. These studies encourage further development of this group of medicinal agents for the treatment of estrogen-dependent mammary carcinoma.

PubMed Disclaimer

Similar articles

Cited by

Publication types

Substances

LinkOut - more resources